BlueRock Therapeutics collaboration over Parkinson’s disease digital health technology
March 15, 2023Medical Communications
Clinical stage biopharmaceutical company BlueRock Therapeutics has announced a collaboration with Rune Labs and Emerald Innovations. It will look at …
DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine
March 15, 2023Business Services
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that …
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further …
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
March 14, 2023Business Services
AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the …
Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved
March 14, 2023Business Services
14 March 2023, Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the …
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration
March 14, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
March 14, 2023Business Services
Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from …
Newron announces 2022 financial results and provides outlook for 2023
March 14, 2023Business Services
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company …
Cell and Gene Therapy Catapult opens new Process Analytical Technologies laboratory
March 14, 2023Business Services
London, 14 March 2023: The Cell and Gene Therapy Catapult (CGT Catapult) today announces the opening of a new laboratory …
US bill pushes Medicare and Medicaid categories for prescription digital therapeutics
March 14, 2023Medical Communications
Both the US House of Representatives and Senate are considering a bill which would encourage the adoption of prescription digital …
GSK shares positive results from meningococcal disease vaccine trial
March 14, 2023Research and Development
GSK has announced positive results from its vaccine candidate trial for meningococcal, which is a significant cause of meningitis and …
Occlutech launches FROST-HF study of heart failure device
March 14, 2023Research and Development
Occlutech has announced that it has recruited its first patient in the FROST-HF study, which aims to investigate the company’s …
Pfizer signs $43bn deal to buy Seagen
March 14, 2023Sales and Marketing
Pharma giant Pfizer has signed a definitive merger agreement valued at $43bn to buy biotech firm Seagen. US-based Seagen …
Scottish patients with the most aggressive form of viral hepatitis become first in UK to be offered routine NHS access to Hepcludex® (bulevirtide)
March 14, 2023Business Services
Monday 13 March 2023, London, UK – Gilead Sciences Ltd today announced that the Scottish Medicines Consortium (SMC) has become …
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023Business Services
KANSAS CITY, KANSAS and PRINCETON, NEW JERSEY – March 13, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing …
BRITISH LAND AND AUSTRALIANSUPER ANNOUNCE LIFE SCIENCES AMBITION AT CANADA WATER
March 13, 2023Business Services
13 March 2023
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
March 13, 2023Business Services
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled …
Richard Stedman rejoins ACG as the CEO of Engineering Division
March 13, 2023Business Services
ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce that …
Sanofi to acquire Provention Bio in $2.9bn deal
March 13, 2023Sales and Marketing
Sanofi has agreed to acquire Provention Bio as part of a $2.9bn deal that aims to improve the company’s portfolio …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
